AbL Diagnostics SA (ABLD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AbL Diagnostics SA (ABLD) has a cash flow conversion efficiency ratio of 0.069x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€479.46K ≈ $560.54K USD) by net assets (€6.93 Million ≈ $8.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
AbL Diagnostics SA - Cash Flow Conversion Efficiency Trend (2017–2023)
This chart illustrates how AbL Diagnostics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of AbL Diagnostics SA for a breakdown of total debt and financial obligations.
AbL Diagnostics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AbL Diagnostics SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gokul Refoils and Solvent Limited
NSE:GOKUL
|
0.080x |
|
DESWELL INDS INC. DL-01
F:DW2
|
N/A |
|
Vrancart Adjud
RO:VNC
|
N/A |
|
Foresta Group Holdings Ltd
AU:FGH
|
-0.582x |
|
Elsoft Research Bhd
KLSE:0090
|
0.004x |
|
KL-Net Corp
KQ:039420
|
0.044x |
|
Arrow Syndicate Public Company Limited
BK:ARROW
|
0.052x |
|
Wonik Cube Corp
KQ:014190
|
0.043x |
Annual Cash Flow Conversion Efficiency for AbL Diagnostics SA (2017–2023)
The table below shows the annual cash flow conversion efficiency of AbL Diagnostics SA from 2017 to 2023. For the full company profile with market capitalisation and key ratios, see how much is AbL Diagnostics SA worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | €6.77 Million ≈ $7.91 Million |
€926.43K ≈ $1.08 Million |
0.137x | +1804.30% |
| 2022-12-31 | €6.75 Million ≈ $7.90 Million |
€-54.25K ≈ $-63.42K |
-0.008x | +62.89% |
| 2021-12-31 | €2.62 Million ≈ $3.06 Million |
€-56.69K ≈ $-66.28K |
-0.022x | -273.21% |
| 2020-12-31 | €2.36 Million ≈ $2.76 Million |
€29.51K ≈ $34.50K |
0.012x | +131.83% |
| 2019-12-31 | €7.09 Million ≈ $8.29 Million |
€-278.40K ≈ $-325.48K |
-0.039x | -446.32% |
| 2018-12-31 | €7.15 Million ≈ $8.36 Million |
€81.10K ≈ $94.82K |
0.011x | -87.62% |
| 2017-12-31 | €7.37 Million ≈ $8.62 Million |
€675.20K ≈ $789.38K |
0.092x | -- |
About AbL Diagnostics SA
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S… Read more